Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B Study of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single Tablet Regimen
2010-024007-27Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Virologic suppression at Week 48. Started Feb 2011; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-024007-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024007-27.